Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Mar 11, 2026 · Filed Mar 11, 2026
The money chief of Edwards Lifesciences sold $673K of Edwards Lifesciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$673,228
Shares × reported transaction price
29 days after results of Feb 10, 2026, 43 days before results of Apr 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $85.09 on Mar 11, 2026, within 3% of its 52-week high, after a 2% rise over the previous 30 trading days
52-week range $67.07 (Apr 8, 2025) to $87.18 (Mar 2, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $83.60 on Jan 27, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.5% | -0.9% | -1.6% |
| 30 days | -7.7% | +3.0% | -10.7% |
| 90 days | +1.6% | +8.9% | -7.3% |
| 180 days | +2.5% | +15.0% | -12.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
CFO sold ~$376K of Edwards Lifesciences
Scheduled in advanceCFO sold ~$664K of Edwards Lifesciences
Scheduled in advance